HPV

Laboratorio di Virologia

Laboratorio di Virologia

  • Aspetti virologici, patogenetici e diagnostici di infezioni virali croniche (virus epatitici, HIV)
  • Valutazione di efficacia di molecole antivirali e ricerca di strategie terapeutiche innovative

Assessing the long-term role of vaccination against hpv after loop electrosurgical excision procedure (Leep): A propensity-score matched comparison

Background: Primary prevention through vaccination is a prophylactic approach aiming to reduce the risk of developing human papillomavirus (HPV)-related lesions. No mature and long-term data supported the adoption of vaccination in women undergoing conization. Methods: This is a retrospective multi-institutional study. Charts of consecutive patients undergoing conization between 2010 and 2014 were collected. All patients included had at least 5 years of follow-up. We compared outcomes of patients undergoing conization plus vaccination and conization alone.

Spotlight on the role of human papillomavirus vaccines

In high income setting, the massive implementation of screening programs has reduced the incidence of cervical cancer, dramatically. However, cervical cancer still remains a major health concern, being one of the most common cause of death for cancer among women. The adoption of primary prevention through vaccination against HPV aims to reduce the prevalence of HPV-related lesions and cervical cancer. Accumulating data highlighted the cost-effectiveness of introducing HPV vaccination for adolescent and young adults.

Recurrence rate after loop electrosurgical excision procedure (LEEP) and laser Conization. A 5-year follow-up study

Objective: Conization aims to remove pre-neoplastic lesions of the uterine cervix. Several techniques for conization have been compared, but evidence regarding the most effective therapeutic option is scant. Here, we aimed to compare the recurrence rate following laser conization and loop electrosurgical excision procedure (LEEP) in patients with high-grade cervical dysplasia (HSIL/CIN2+). Methods: This is a retrospective multi-institutional study. Medical records of consecutive patients with HSIL/CIN2+ undergoing conization between 2010 and 2014 were retrieved.

Advances in the management of HPV-related oropharyngeal cancer

Patients with human papillomavirus- (HPV-) related oropharyngeal squamous cell carcinoma (OPSCC) have a better prognosis
than HPV-negative OPSCC when treated with standard high-dose cisplatin-based chemoradiotherapy. Consistent with this
assertion and due to younger age at diagnosis, novel approaches tominimize treatment sequelaewhile preserving survival outcomes
become of paramount importance. Here, we critically reviewed the evidence-based literature supporting the deintensification

Human papillomavirus (HPV) vaccine and HPV-related head and neck cancer: what's next?

Head and neck cancer (HNC) represents one of the most challenging malignancies to treat in adults. During the past years, major advances in multimodal therapeutic regimen including surgery, radiation therapy and chemotherapy have helped to substantially improve prognosis and quality of life in HNC patients. Today, a significant amount of HNC is human papilloma virus (HPV) related and mainly includes patients who are aged <60 years with early T stage and advanced nodal disease. HPV status strongly influences prognosis [1].

HPV-related vulvar diseases and perspectives of p16INK4a immunochemistry: a review of the literature

Two different types of vulvar intraepithelial neoplasia (VIN), HPV-related and HPV-unrelated, should be considered as two separate entities with different management options. The incidence of HPV-related VIN is increasing worldwide and is implicated in carcinogenesis. Our objective is to investigate the use of p16INK4a immunostaining or p16INK4a/p53 double staining for the detection of HPV-related disease to overcome the problem that histological criteria often have significant overlap.

Interferon lambda4 polymorphism is not associated with human papillomavirus infection outcome

Interferon (IFN) lambdas are important specific components of the mucosal innate immune response. The IFN lambda 4 (IFNL4) dinucleotide polymorphism (ΔG/TT) determines the IFN lambdas and related Interferon-stimulated genes activation, in HCV and other chronic infections. Our group first reported that IFN Lambda response was impaired in high-risk Human Papillomavirus (HPV) cervical infections and in precancerous lesions. Accordingly, we sought to evaluate the possible role of the IFNL4 polymorphism in determining HPV infection outcome.

© Università degli Studi di Roma "La Sapienza" - Piazzale Aldo Moro 5, 00185 Roma